Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROGLYCERIN vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing c GMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute angina pectoris,Prophylaxis of angina pectoris,Acute myocardial infarction (IV formulation),Heart failure associated with acute myocardial infarction (IV),Anal fissure (topical, off-label),Esophageal spasm (off-label)
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Terminal half-life: 1–4 minutes for the parent compound; clinical effects dissipate within the same time frame, correlating with rapid metabolism.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Metabolized primarily by hepatic glutathione-organic nitrate reductase and cytochrome P450 enzymes (CYP3A4) to inorganic nitrite and denitrated metabolites; also undergoes extrahepatic metabolism in erythrocytes and vascular tissue.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Metabolized extensively by hepatic glutathione-organic nitrate reductase and other non-specific esterases; renal excretion of metabolites accounts for approximately 50%, with fecal elimination of about 20-30%. Less than 1% of unchanged drug is excreted renally.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Approximately 60% bound to albumin.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
Approximately 3.3 L/kg, indicating extensive distribution into tissues.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Sublingual: 40–60% due to first-pass metabolism; buccal: 40–60%; transdermal: 10–20% (limited by skin permeability).
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No dose adjustment required for any degree of renal impairment, including end-stage renal disease.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Consider 25% dose reduction; Child-Pugh Class C: Avoid use or use with extreme caution, consider 50% dose reduction.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Safety and efficacy not established; limited data: IV infusion 0.25-1 mcg/kg/min titrated to effect; sublingual 5-10 mcg/kg per dose (max 0.6 mg) every 5-10 minutes as needed for angina.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Start at lowest dose; sublingual 0.3 mg, transdermal 0.2 mg/hour; increased sensitivity to hypotension and syncope; monitor for orthostatic hypotension; may require reduced dosing frequency.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
Do not use nitroglycerin with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Concomitant use with soluble guanylyl cyclase stimulators (e.g., riociguat) is contraindicated.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension,Tachycardia,Paradoxical bradycardia,Increased intracranial pressure (use with caution in cerebral hemorrhage or head trauma),Hypertrophic cardiomyopathy (may exacerbate outflow obstruction),Tolerance with prolonged use (intermittent dosing with nitrate-free interval recommended),Abrupt withdrawal may precipitate angina
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin or any component,Concomitant use with phosphodiesterase-5 inhibitors (within 24 hours for sildenafil, vardenafil; 48 hours for tadalafil),Concomitant use with soluble guanylyl cyclase stimulators (riociguat),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis,Pericardial tamponade,Restrictive cardiomyopathy,Acute myocardial infarction with low left ventricular filling pressure,Circulatory failure (shock)
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Avoid alcohol consumption while taking nitroglycerin due to risk of severe hypotension and syncope. No other significant food interactions.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
Insufficient human data; animal studies do not indicate teratogenicity. Avoid in first trimester unless clearly needed. No known increased risk of major malformations. Use caution in third trimester due to potential maternal hypotension reducing uteroplacental perfusion.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Excreted into breast milk in very low amounts; M/P ratio not established. Considered compatible with breastfeeding; monitor infant for hypotension.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
No routine dose adjustment required; however, increased plasma volume may necessitate higher doses for therapeutic effect. Monitor clinical response.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
Use with caution in patients with hypertrophic obstructive cardiomyopathy due to risk of syncope. Nitroglycerin is contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to severe hypotension. Sublingual tablets should be taken at first sign of angina; if pain persists after 5 minutes, call 911. Tolerance develops with continuous exposure, so use nitrate-free intervals (10-12 hours daily) for transdermal patches. Administer intravenous nitroglycerin with non-PVC tubing to avoid drug absorption. Monitor for hypotension, reflex tachycardia, and headache. Do not use in patients with severe anemia, increased intracranial pressure, or right ventricular infarction.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Take sublingual nitroglycerin at the first sign of chest pain; sit down before taking to prevent dizziness.,Place the tablet under the tongue or in the buccal pouch and allow it to dissolve completely; do not swallow.,If pain is not relieved within 5 minutes, call 911 immediately; you may take a second tablet while waiting.,Do not take this medication if you have taken erectile dysfunction drugs (e.g., sildenafil, tadalafil) within the last 24-48 hours.,Store sublingual tablets in the original glass bottle with the cap tightly closed to protect from light and moisture; do not transfer to another container.,Expect a headache or flushing after taking; these usually diminish with continued use.,If using a transdermal patch, apply to a hairless area of skin and rotate sites daily; remove at bedtime to prevent tolerance.,Avoid alcohol while taking this medication as it can increase the risk of hypotension.,Seek emergency help if you experience severe dizziness, fainting, or difficulty breathing.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
"Concomitant use of nitroglycerin, a vasodilator that increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, and acebutolol, a cardioselective beta-1 adrenergic blocker, can lead to excessive hypotension and reflex tachycardia. Acebutolol may blunt the compensatory sympathetic response to nitroglycerin-induced vasodilation, while nitroglycerin can counteract the negative chronotropic effects of acebutolol, resulting in unopposed vagal tone and potential bradycardia. This interaction increases the risk of syncope, dizziness, and cardiovascular collapse, particularly in patients with volume depletion or pre-existing heart failure."
"Amobarbital, a barbiturate with hepatic enzyme-inducing properties, may enhance the metabolism of nitroglycerin, potentially reducing its efficacy. However, the primary concern is that amobarbital can cause significant hypotension via central nervous system depression and vasodilation, which, when combined with the vasodilatory effects of nitroglycerin, may lead to additive hypotensive effects, increasing the risk of severe hypotension, syncope, and cardiovascular collapse. This interaction is particularly relevant in patients with coronary artery disease or heart failure, where maintaining adequate blood pressure is critical."
"Concurrent administration of clofarabine, a purine nucleoside antimetabolite, and nitroglycerin, a vasodilator for angina, may lead to additive hypotension. Clofarabine itself can induce hypotension as an adverse effect, and nitroglycerin directly relaxes vascular smooth muscle, resulting in decreased blood pressure. This combination increases the risk of severe hypotension, potentially leading to dizziness, syncope, or falls, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROGLYCERIN vs MONOKET, answered by our medical review team.
NITROGLYCERIN is a Nitrate Vasodilator that works by Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing c GMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROGLYCERIN and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROGLYCERIN is: Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROGLYCERIN and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROGLYCERIN is classified as Category C. Insufficient human data; animal studies do not indicate teratogenicity. Avoid in first trimester unless clearly needed. No known increased risk of major malformations. Use caution . MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.